Full Press Release Details
Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update.
LXRX
Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update
Key Takeaway: Lexicon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical Update
Price reaction · baseline $3.58 (2021-07-29 close) · hit after-hours · clean, no other LXRX news in the window
day 0 close
-1.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+111%
120-day peak, hindsight
Typical move
11%
average across 13 past catalysts
Cash runway
~61 mo
Minimal dilution risk
Lead asset
Sotagliflozin
Phase 3 · Type 1 Diabetes Mellitus